Compound Design by Fragment‐Linking
暂无分享,去创建一个
Mark Whittaker | R. Law | J. Barker | M. Whittaker | O. Ichihara | Richard J Law | Osamu Ichihara | John Barker
[1] Keiji Morokuma,et al. Molecular Orbital Studies of Hydrogen Bonds. III. C=O···H–O Hydrogen Bond in H2CO···H2O and H2CO···2H2O , 1971 .
[2] Kazuo Kitaura,et al. A new energy decomposition scheme for molecular interactions within the Hartree‐Fock approximation , 1976 .
[3] Hideaki Umeyama,et al. The origin of hydrogen bonding. An energy decomposition study , 1977 .
[4] W. Jencks,et al. On the attribution and additivity of binding energies. , 1981, Proceedings of the National Academy of Sciences of the United States of America.
[5] P. Hajduk,et al. Discovering High-Affinity Ligands for Proteins: SAR by NMR , 1996, Science.
[6] D A Dougherty,et al. Cation-pi interactions in aromatics of biological and medicinal interest: electrostatic potential surfaces as a useful qualitative guide. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[7] Jean M. Severin,et al. Discovery of Potent Nonpeptide Inhibitors of Stromelysin Using SAR by NMR , 1997 .
[8] P. Hajduk,et al. Stromelysin Inhibitors Designed from Weakly Bound Fragments: Effects of Linking and Cooperativity , 1997 .
[9] D. A. Dougherty,et al. Cation-π interactions in structural biology , 1999 .
[10] K. Kitaura,et al. Fragment molecular orbital method: an approximate computational method for large molecules , 1999 .
[11] Dustin J Maly,et al. Combinatorial target-guided ligand assembly: identification of potent subtype-selective c-Src inhibitors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[12] Harren Jhoti,et al. High-throughput crystallography for lead discovery in drug design , 2002, Nature Reviews Drug Discovery.
[13] R. Griffey,et al. SAR by MS: a ligand based technique for drug lead discovery against structured RNA targets. , 2002, Journal of medicinal chemistry.
[14] Marcel L. Verdonk,et al. The consequences of translational and rotational entropy lost by small molecules on binding to proteins , 2002, J. Comput. Aided Mol. Des..
[15] Gang Liu,et al. Fragment screening and assembly: a highly efficient approach to a selective and cell active protein tyrosine phosphatase 1B inhibitor. , 2003, Journal of medicinal chemistry.
[16] Gang Liu,et al. Discovery of a potent, selective protein tyrosine phosphatase 1B inhibitor using a linked-fragment strategy. , 2003, Journal of the American Chemical Society.
[17] M. Congreve,et al. Fragment-based lead discovery , 2004, Nature Reviews Drug Discovery.
[18] Jeffrey W. Bode,et al. Reactor ChemAxon Ltd., Maramaros koz 2/a, Budapest, 1037 Hungary. www.chemaxon.com. Contact ChemAxon for pricing information. , 2004 .
[19] 末永 正彦,et al. PC GAMESSのための新しい計算化学統合環境 Facio の開発 , 2005 .
[20] Gianni Chessari,et al. Application of fragment screening and fragment linking to the discovery of novel thrombin inhibitors. , 2006, Journal of medicinal chemistry.
[21] Christopher W. Murray,et al. Entropic Consequences of Linking Ligands , 2006 .
[22] P. Hajduk,et al. Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis. , 2006, Journal of medicinal chemistry.
[23] Lisa M. Shewchuk,et al. Crystallization of protein–ligand complexes , 2006, Acta crystallographica. Section D, Biological crystallography.
[24] T. Hesterkamp,et al. Fragment based drug discovery using fluorescence correlation: spectroscopy techniques: challenges and solutions. , 2007, Current topics in medicinal chemistry.
[25] G. Siegal,et al. Fragment‐Based Synthesis and SAR of Modified FKBP Ligands: Influence of Different Linking on Binding Affinity , 2007, ChemMedChem.
[26] P. Hajduk,et al. A decade of fragment-based drug design: strategic advances and lessons learned , 2007, Nature Reviews Drug Discovery.
[27] T Neumann,et al. SPR-based fragment screening: advantages and applications. , 2007, Current topics in medicinal chemistry.
[28] Kazuo Kitaura,et al. Extending the power of quantum chemistry to large systems with the fragment molecular orbital method. , 2007, The journal of physical chemistry. A.
[29] Kazuo Kitaura,et al. Pair interaction energy decomposition analysis , 2007, J. Comput. Chem..
[30] Edward R Zartler,et al. Practical aspects of NMR-based fragment discovery. , 2007, Current topics in medicinal chemistry.
[31] Alexander A Alex,et al. Fragment-based drug discovery: what has it achieved so far? , 2007, Current topics in medicinal chemistry.
[32] Tomonaga Ozawa,et al. The importance of CH/pi hydrogen bonds in rational drug design: An ab initio fragment molecular orbital study to leukocyte-specific protein tyrosine (LCK) kinase. , 2008, Bioorganic & medicinal chemistry.
[33] Masahiko Suenaga,et al. Development of GUI for GAMESS / FMO Calculation , 2008 .
[34] E. Freire. Do enthalpy and entropy distinguish first in class from best in class? , 2008, Drug discovery today.
[35] Mark Whittaker,et al. Fragment-based activity space: smaller is better. , 2008, Current opinion in chemical biology.
[36] Tjelvar S. G. Olsson,et al. The thermodynamics of protein-ligand interaction and solvation: insights for ligand design. , 2008, Journal of molecular biology.
[37] M. Congreve,et al. Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.
[38] Chris Abell,et al. Application of fragment growing and fragment linking to the discovery of inhibitors of Mycobacterium tuberculosis pantothenate synthetase. , 2009, Angewandte Chemie.
[39] A. Alex,et al. Thermodynamic Optimisation in Drug Discovery: A Case Study using Carbonic Anhydrase Inhibitors , 2009, ChemMedChem.
[40] Yoshihisa Inoue,et al. Cl–π Interactions in Protein–Ligand Complexes , 2009 .
[41] L. Mario Amzel,et al. Impact of linker strain and flexibility in the design of a fragment-based inhibitor , 2009, Nature chemical biology.
[42] Gianni Chessari,et al. From fragment to clinical candidate--a historical perspective. , 2009, Drug discovery today.
[43] Claudio Luchinat,et al. Entropic contribution to the linking coefficient in fragment based drug design: a case study. , 2010, Journal of medicinal chemistry.
[44] Thomas Hesterkamp,et al. Fragments: past, present and future. , 2010, Drug discovery today. Technologies.
[45] György G Ferenczy,et al. Thermodynamics guided lead discovery and optimization. , 2010, Drug discovery today.
[46] Mark Whittaker,et al. Discovery of a Novel Hsp90 Inhibitor by Fragment Linking , 2010, ChemMedChem.
[47] Amit Choudhary,et al. n→π* Interactions in Proteins , 2010, Nature chemical biology.
[48] M. Krohn,et al. Discovery of 4-[(2S)-2-{[4-(4-chlorophenoxy)phenoxy]methyl}-1-pyrrolidinyl]butanoic acid (DG-051) as a novel leukotriene A4 hydrolase inhibitor of leukotriene B4 biosynthesis. , 2010, Journal of medicinal chemistry.
[49] Chris Abell,et al. Optimization of the interligand Overhauser effect for fragment linking: application to inhibitor discovery against Mycobacterium tuberculosis pantothenate synthetase. , 2010, Journal of the American Chemical Society.